TCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit

Rhea-AI Summary

TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy firm, will participate in a fireside chat at the Jefferies Cell & Genetic Medicine Summit on September 29 at 2:00PM E.T. This event allows investors to gain insights into the company's innovative T cell therapies targeting solid tumors. A live webcast will be available on the company's Investors page, and a replay will be accessible for 30 days post-event.

TCR² develops proprietary TRuC^®-T cells designed to target cancer cells effectively.

CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at the Jefferies Cell & Genetic Medicine Summit on Thursday, September 29 at 2:00PM E.T.

A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.

About TCR2 Therapeutics

TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC^®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR², please visit www.tcr2.com.

Investor and Media Contact:
Carl Mauch
Senior Director, Investor Relations and Corporate Communications
(617) 949-5667
carl.mauch@tcr2.com

FAQ

What is the date and time of TCRR's fireside chat at the Jefferies Cell & Genetic Medicine Summit?

TCRR's fireside chat is scheduled for September 29 at 2:00PM E.T.

Where can I watch the TCRR fireside chat live?

The live webcast can be watched on TCRR's Investors page at www.investors.tcr2.com.

How long will the archived replay of TCRR's presentation be available?

The archived replay will be available for at least 30 days following the presentation.

What is the focus of TCR² Therapeutics?

TCR² Therapeutics focuses on developing novel T cell therapies for patients with solid tumors.

What technology does TCRR use for its cancer therapies?

TCRR utilizes a proprietary technology called TRuC^®-T cells that specifically target and kill cancer cells.